The standpoint of gene therapy programs

Drug News and Perspectives

Volumn 20, Issue 5, 2007, Pages 335-343

  Romano, Gaetano ^a  

^a Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; COMPLEMENTARY DNA; CONNECTIVE TISSUE GROWTH FACTOR; DNA VACCINE; EGEN 001; INTERLEUKIN 13; INTERLEUKIN 24; NANOCARRIER; PLASMID DNA; PROSTACYCLIN SYNTHASE; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VAXFECTIN;

ABDOMINAL CRAMP; ANTIGEN PRESENTING CELL; CANCER PREVENTION; CANCER THERAPY; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ELECTROPORATION; FEVER; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC IMMUNIZATION; GENETIC TRANSFECTION; HUMAN; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; RECURRENT CANCER;

ANIMALS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 34548351286     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Romano, G., Micheli, P., Pacilio, C. and Giordano, A. Latest developments in gene transfer technology: achievements, perspectives, and controversies over therapeutic applications. Stem Cells 2000, 18: 19-39.
2. Romano, G., Pacilio, C. and Giordano, A. Gene transfer technology in therapy: current applications and future goals. Stem Cells 1999, 17: 191-202.
3. Romano, G. Gene transfer in experimental medicine. Drug News Perspect 2003, 16: 267-276.
4. Romano, G. Current development of lentiviral-mediated gene transfer. Drugs News Perspect 2005, 18: 128-134.
5. Romano, G. The controversial role of adenoviral-mediated gene transfer in gene therapy programs: where do we stand? Drugs News & Perspect 2006, 19: 99-106.
6. Shirakawa, T., Gotoh, A., Terao, S. et al. Long-term results of a phase I/II study of Ad-OC-TK/V AL gene therapy for the patients with metastatic or local recurrent prostate cancer. Mol Ther 2007, 15(Suppl.):Abst729.
7. Nemunaitis, M., Senzer, N., Zhang, Y.A. et al. Phase I study of intratumoral (IT) injection with a telomerase specific conditionally replicative adenovirus (CRAd) telomelysin(OBP-301), in patients with advanced solid tumor. Mol Ther 2007, 15(Suppl.):Abst 728.
8. Nemunaitis, J.J., Bier-Laninig, C., Calyman, G.L. et al. Prognostic determinants associated with efficacy of adenoviral p53 gene therapy (Advexin) in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Mol Ther 2007, 15(Suppl.):Abst 45.
9. Griffith, T.S., Konety, B.R., Joudy, F.N. et al. Phase I study of Ad5-TRAIL in men with clinically organ confined prostate cancer. Mol Ther 2007, 15(Suppl.): Abst 44.
10. Chada, S., Nemunaitis, J., Tong, A. et al. Clinical experience with the mda-7/IL-24 tumor suppressor. Mol Ther 2007, 15(Suppl.): Abst 380.
11. Jensen, M.C., Popplewell, L., DiGiusto, D.L. et al. A first-in-human clinical trial of adoptive therapy using CD19-specific chimeric antigen receptor re-directed T cells for recurrent/refractory: follicular lymphoma. Mol Ther 2007, 15(Suppl.): Abst 372.
12. Wakabayashi, T., Mizuno, M., Natsume, A. et al. A phase I clinical trial of liposome-mediated interferon-beta gene therapy for high-grade gliomas. Mol Ther 2007, 15(Suppl.):Abst 179.
13. Senzer, N. Combined modality therapy of locally advanced pancreas cancer (LAPC) integrating radiation inducible gene therapy with TNFerade™: preliminaty results of a randomized phase II/III trial. Mol Ther 2007, 15(Suppl.): Abst 1050.
14. - CTL clones. Mol Ther 2007, 15(Suppl.): Abst 1051.
15. Anwer, K.N., Barnes, M.N., Anderson, M.L. et al. Progress in the clinical development of a novel IL-12 gene therapeutic for the treatment of recurrent ovarian cancer. Mol Ther 2007, 15(Suppl.): Abst 182.
16. Kang, E.M., Linton, G., Theobaldi, N. et al. Transplantation of genetically modified cells for treatment of infection in patients with X-linked chronic granulomatous disease (X-CGD). Mol Ther 2007, 15(Suppl.): Abst 768.
17. Sokolik, R.A., Podsakoff, G., Muul, L. et al. Gene therapy in adenosine deaminase-deficient children with autologous bone marrow cells transduced with two retroviral vectors after withdrawal of enzyme replacement treatment and low-dose chemotherapy. Mol Ther 2007, 15(Suppl.): Abst 249.
18. Schwarzwaelder, K., Schmidt, M., Deichman, A. et al. In vivo expansion of integration clones caused by retroviral activation of MDSI-Evll, PRDM16 or SETBP1 in a successful clinical chronic granulomatous disease (CGD) gene therapy trial. Mol Ther 2007, 15(Suppl.): Abst 240.
19. Mingozzi, F., Meulenberg, J., Hui, D. et al. Intramuscular administration of an AAV-1 vector in humans results in capsid-specific T cell responses. Mol Ther 2007, 15(Suppl.): Abst 1056.
20. Flotte, T.R., Brantly, M.L., Spencer, L.T. et al. Phase I clinical trials of intramuscular injection of rAAV2 and rAAV1-pseudotyped versions of an alpha-1 antitrypsin (AAT) vector in AAT-deficient adults. Mol Ther 2007, 15(Suppl.): Abst 1054.
21. Mease, P.J., Heald, A.E. and Anklesaria, P. A phase 1/2 clinical study of intra-articular administration of a recombinant adeno-associated vector containing a TNF-α antagonist gene in inflammatory arthritis. Mol Ther 2007, 15(Suppl.): Abst 1053.
22. Sawicki, J.A., Huang, Y.H., Peng, W. et al. Nanoparticle-delivery of diphteria toxin DNA inhibits ovarian tumor growth. Mol Ther 2007, 15(Suppl.): Abst 43.
23. Liu, C., Erlichman, C., McDonald, C.J. et al. Heat shock protein inhibitors increase the efficacy of measles virotherapy. Mol Ther 2007, 15(Suppl.): Abst 47.
24. Allen, C., Paraskevakou, G., Iankov, I. et al. IL-13 displaying retargeted oncolytic measles virus (MV) strains have significant activity and improved therapeutic index against gliomas. Mol Ther 2007, 15(Suppl.): Abst 51.
25. Wu, L., Altomonte, J., Chen, L. et al. Exponential enhancement of oncolytic VSV potency by vector-mediated suppression of anti-viral inflammatory responses in vivo. Mol Ther 2007, 15(Suppl.): Abst 49.
26. Kelly, E., Hadac, E. and Russell S.J. Targeting tissue tropism of coxsackievirus A21, an oncolytic enterovirus. Mol Ther 2007, 15(Suppl.): Abst 52.
27. Fewell, J.G., Rice, J.R., Hickman, M. et al. Treatment of metastatic renal cell cancer using multiple IV administrations of IL-12 plasmid nanoparticles. Mol Ther 2007, 15(Suppl.): Abst 170.
28. Cheng, W.F., Chen, C.A., Hsieh, C.Y. et al. Connective tissue growth factor encoding tumor antigen generates potent antigen-specific cancer immunotherapy through prolonging life span of antigen-presenting cells. Mol Ther 2007, 15(Suppl.): Abst 35.
29. Brown, C.E., Starr, R., Aguilar, B. et al. Targeted elimination of stem-like glioma progenitors with genetically engineered cytolytic Tcells. Mol Ther 2007, 15(Suppl.): Abst 598.
30. Giordano, A., Fucito, A., Romano, G. and Marino I.R. Carcinogenesis and environment: the cancer stem cell hypothesis and implications for the development of novel therapeutics and diagnostics. Front Biosci 2007, 12: 3475-82.
31. Gan, D.D., Macaluso, M., Cinti, C. et al. How does a normal cell become a cancer cells? J Exp Clin Cancer Res 2003, 22: 509-16.
32. Romano, G. The role of adult stem cells in carcinogenesis. Drug News Perspect 2005, 18: 555-9.
33. Pringle, I.A., Lawton, A.E., Green, A.M. et al. Generation of a CpG-free clinical trial plasmid for cystic fibrosis lung gene therapy. Mol Ther 2007, 15(Suppl.): Abst 1018.
34. Lawton, A.E., Dabies, L.A., Yew, N.S. et al. CpGs influence the duration of gene expression from plasmid vectors after in vivo lung delivery. Mol Ther 2007, 15(Suppl): Abst 342.
35. Ito, T., Okada, T., Mimuro, J. et al. AAV vector-mediated sustained expression of prostacyclin synthethase ameliorates obesity in Zucker fatty rats. Mol Ther 2007, 15(Suppl.): Abst 359.
36. Yoshioka, T., Okada, T., Maeda, Y. et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atheriosclerosis in apolipoprotein E-deficient mice. Gene Ther 2004, 11: 1772-9.
37. Zhou, Q., Imam, S.Z., He, W. et al. Macrophage delivery of GDNF ameliorates neurodegeration in Parkinson's disease. Mol Ther 2007, 15(Suppl.): Abst 527.
38. Manfredsson, F.P., Lewin, A.S., Burger, C. et al. rAAV mediated Parkin over-expression partially ameliorates the behavioral effects of the 6-hydroxy dopamine lesion. Mol Ther 2007, 15(Suppl.): Abst 529.
39. Perrin, V., Dufour, N., Raoul, C. et al. Activation of the JNK pathway in a rat model of HD and implication in the pathology. Mol Ther 2007, 15(Suppl.): Abst 536.
40. Kells, A.P., Henry, R.A., Hughes, S.M. et al. Attenuation of functional deficits in the QA model of Huntington's disease following AAV therapeutic delivery. Mol Ther 2007, 15(Suppl.): Abst 545.
41. Desai, M.K., Mastrangelo, M.A., Janelsins, M.C. et al. Investigating the role of MCP-1 in early Alzheimer's disease via rAAV-mediated hippocampal gene transfer in a triple transgenic mouse model. Mol Ther 2007, 15(Suppl.): Abst 539.
42. Kamata, M., Susanto, M.T., Irvin S., et al. Gene therapy approach for transthyretin amyloidosis using a lentiviral vector expressing the transsuppressor variant. Mol Ther 2007, 15(Suppl.): Abst 540.
43. Zelenaia, O., Lui, X., McDonnell, J. et al. Evaluation of formulation and stability of investigational gene transfer vectors for Leber congenital amaurosis. Mol Ther 2007, 15(Suppl.): Abst 525.
44. Kan, O., Nicoud, M., Iqball, S. et al. The evaluation of novel specific promoters in an EIAV lentiviral vector for targeting gene expression in the photoreceptors of the eye. Mol Ther 2007, 15(Suppl.): Abst 673.
45. McCormack, M.P., Rabbitts, T.H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350: 913-22.
46. Beard, B.C., Dickerson, D., Beebe, K. et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 2007, 15(Suppl.): Abst 66.
47. Moldt, B., Staunstrup, N.H., Jakobsen M. et al. Site-specific genomic integration of lentiviral DNA circles. Mol Ther 2007, 15 (Suppl.): Abst 69.
48. Liu, M., Sabo, P.J., Kuen M.S. et al. Assessing gammaretroviral integration preferences for DNAse hypersensitive sites. Mol Ther 2007, 15(Suppl.): Abst 70.
49. Hacker, C.V., Moal, Y.D., Ralph, G.S. et al. Determination of the profile and site preference of lentiviral vector integration in vivo and in primary astrocyte cultures. Mol Ther 2007, 15(Suppl.): Abst 71.
50. Zychlinski, D., Schambach, A., Modlich, U. et al. Self-inactivating retroviral vectors harboring cellular promoters reduce the risk of insertional transactivation and transformation. Mol Ther 2007, 15(Suppl.): Abst 1061.
51. Bauche, C., Gaussin, A., De Royer, J. et al. Identification of genetic insulator elements for safe gene therapy viral integrating vectors. Mol Ther 2007, 15(Suppl.): Abst 73.
52. Mitra, K., Su M. and Lenz, J. Multiple tandem insulators may reduce retroviral insertional activation of oncogenes and lymphomagenesis. Mol Ther 2007, 15(Suppl.): Abst 67.
53. Koldej, R. and Anson D.S. Improving the safety of HIV-1 derived gene therapy vec tors: reducing the rale of SIN repair and polyadenylation signal readthrough. Mol Ther 2007, 15(Suppl.): Abst 68.
54. Schambach, A., Galla, M., Maetzing, T. et al. Exploiting the terminal repeats of lentiviral and gammaretroviral vectors to block transcriptional readthrough and enhancer insulators. Mol Ther 2007, 15(Suppl.): Abst 327.
55. Joseph, G., Jasti, A., Sastry, L. et al. LTR attachment site mutant non-integrating lentiviral vectors provide greater levels of gene expression. Mol Ther 2007, 15(Suppl.): Abst 325.
56. Bayer, M.A., Zeithaml, B., Kantor, B. et al. Characterizing the molecular mechanism for robust, sustained hepatic expression from episomal lentiviral vectors. Mol Ther 2007, 15(Suppl.): Abst 782.
57. Romano, G. Current development of adenoassociated viral vectors. Drug News Perspect 2005, 18: 311-6.
58. Miller, D.G., Donsante, A., Li, Y. et al. AAV vector integration at a common locus leads to hepatocellular carcinoma in mice. Mol Ther 2007, 15(Suppl.): Abst 1.
59. Romano, G. Advances and perspectives in the field of gene transfer technology. Drug News Perspect 2006, 19: 359-68.
60. Moldt, B., Andersen, P.R., Yant, S.R. et al. Terminal inverted repeats of the Sleeping Beauty DNA transposon possess residual promoter-like activities. Mol Ther 2007, 15(Suppl.): Abst 338.
61. Ehrhardt, A., Xu, H., Huang, Z. et al. A direct comparison of two non viral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage phiC31 and the Sleeping Beauty transposase. Mol Ther 2005, 11: 695-706.
62. Keravala, A., Lee, S., Thyagarajan, B. et al. Mutational derivatives of PhiC31 integrase with increased efficiency and specificity. Mol Ther 2007, 15(Suppl.): Abst 337.
63. Papapetrou, E.P., Ziros, P.G., Micheva, I.D. et al. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther 2006, 13: 40-51.
64. Argyros, O., Wong, S.P., Waddington, S. et al. Development of S-MAR plasmid vectors for persistent expression and maintenance in vivo. Mol Ther 2007, 15(Suppl.): Abst 344.
65. Scott, J.M., Voss, T.T., Appledorn, D.M. et al. Adenovirus induced innate immune responses are mediated in part by the presence of natural antibodies in Ad naïve mice. Mol Ther 2007, 15(Suppl.): Abst 660.
66. Wortmann, A., Vohringer, S., Engler, T. et al. Fully detargeted polyethylene glycol-stealthed adenovirus vectors demonstrate high potency for genetic vaccination and are able to escape from pre-existing anti-Ad humoral immunity. Mol Ther 2007, 15(Suppl.): Abst 10.
67. Wonganan, P., Leggiero, E., Brasky, K. et al. Toxicology of PEGylated hlper-dependent adenovirus in non-human primates. Mol Ther 2007, 15(Suppl.): Abst 13.
68. Bruder, J.T., Chen, P., Konovalova, S. et al. Multivalent adenovector-based malaria vaccine induces high levels of functional antibodies. Mol Ther 2007, 15(Suppl.): Abst 148.
69. Vilalta, A., Pan, C.H., Jimenez, G. et al. Vaxfectin™-formulated plasmid DNA measles vaccine elicits protective immune response in non-human primates. Mol Ther 2007, 15(Suppl.): Abst 145.
70. Tang, Y., Akbulut, H., Maynard, J. et al. Vector prime-protein boost vaccine for avian and human influenza viruses. Mol Ther 2007, 15(Suppl.): Abst 150.
71. Liu, T.H., Oscherwitz, J., Schnepp, B. et al. Novel genetic vectors for Anthrax based on recombinant AAV vectors. Mol Ther 2007, 15(Suppl.): Abst 151.
72. Ahlen G.F., Soderholm, J., Tjelle, T. et al. In vivo electroporation promotes intra-muscular DNA uptake, protein expression, and inflammation at the site of injection, which greatly enhances the immunogenicity of hepatitis C virus non-structural 3/4A DNA. Mol Ther 2007, 15(Suppl.): Abst 161.
73. Doody, T.G., Piggott, J.M., Forde, P.F. et al. Comparison of electroporatively delivered non-compacted and compacted DNA. Mol Ther 2007, 15(Suppl.): Abst 917.
74. Lin, F., Groderick, K., Soderholm, J. et al. A single-needle device for electroporation-enhanced DNA delivery. Mol Ther 2007, 15(Suppl.): Abst 504.
75. Kjeken, R., Mathiesen, I., Lin, F. et al. A CE-marked automated device for electroporation-enhanced DNA delivery in humans. Mol Ther 2007, 15(Suppl.): Abst 503.
76. Storer, W.A., Thompson, D.F., Bondioli, K. et al. GnRH-epxressing plasmid delivery by constant-current electroporation can require the reproductive axis in horses. Mol Ther 2007, 15(Suppl.): Abst 17.
77. Heller, R., Jaroszeski, M.J., Cruz, Y. et al. Non-viral cutaneous gene transfer DNA using in vivo electroporation. Mol Ther 2007, 15(Suppl.): Abst 18.
78. Gissel, H., Moller, P.H. and Gehl, J. Optimized pulses for electro gene transfer to muscle tissue reduce adverse effects on cellular integrity and function. Mol Ther 2007, 15(Suppl.): Abst 19.
79. Endo, H., Tachibana, K., Feril, L.B and Yamaguchi, K. Enhanced gene transfer by echo contrast agents: comparison between BR1 and BR14 in vitro and in vivo. Mol Ther 2007, 15(Suppl.): Abst 923.
80. Li, Y.S. and McHale A.P. Studies on ultrasound-mediated transient cell membrane permeabilization (sonoporation) events in vitro. Mol Ther 2007, 15(Suppl.): Abst 922.
81. Carvalho, L.P., Takeshita, D., Carillo, B. et al. Hydrodynamics and ultrasound-based transfection of heart with plasmid DNA. Mol Ther 2007, 15(Suppl.): Abst 488.
82. Shen, Z., Brayman, A.A., Chen, L. et al. Optimization of microbubble concentration and acoustic pressure increases ultrasound-mediated gene transfer efficiency while reduces tissue damage. Mol Ther 2007, 15(Suppl.): Abst 20.
83. Suda, T. and Liu, D. Development of computer-controlled injection device for hydrodynamic gene delivery. Mol Ther 2007, 15(Suppl.): Abst 22.
84. Hibbitt, O.C., Harbottle, R.P., Waddington, S.N. et al. Efficient delivery and long-term expression of a 135 kb LDLR genomic DNA locus in vivo following hydrodynamic tail veil injection. Mol Ther 2007, 15(Suppl.): Abst 23.
85. Podetz-Pedersen, K., Bell, J.B., McIvor, R.S. and Hackett, P.B. Comparative gene expression in vivo after hydrodynamic delivery and polyethyleneimine-conjugated delivery of DNA using the Sleeping Beauty transposon system. Mol Ther 2007, 15(Suppl.): Abst 24.